CasNo： 66004-57-7
Molecular Formula： C78H123N23O22S2
| IUPAC Name | [(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl] (4S)-5-[[2-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-3-phenylpropanoyl]oxy-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2R)-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]-3-sulfanylidenepropanoyl]amino]pentanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoate |
| Description | somatotropin (176-191) is an useful chemical compound. |
| Uses | Somatotropin (176-191), also known as AOD-9604, is a synthetic peptide derived from the human growth hormone (hGH). It consists of the amino acid sequence 176-191 of the hGH peptide. This fragment is believed to represent the lipolytic, or fat-burning, region of the hormone. |
This article looks at the ongoing confusion regarding non-approved substances and the regulatory status of the drug somatotropin (176-191).
Fragment 176-191 peptide, also known as HGH Fragment 176-191 or modified AOD-9604, has been proposed by researchers through laboratory experiments to possibly stimulate weight reduction and fat burn, in addition to helping to elevate IGF-1 levels in test subjects.